75.51% -0.555

Avenue Therapeutics Inc (ATXI)

Überblick Nachrichten Preisverlauf Financials Warum fällt ATXI? Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

24-Stunden-Volumen:

Relative Volume:

Marktkapitalisierung:

Nettoeinkommen (Verlust:

Netto-Cashflow:

1W Leistung:

1M Leistung:

6M Leistung:

1J Leistung:

1-Tages-Spanne:

1-Wochen-Bereich:

52-Wochen-Spanne:

Avenue Therapeutics Inc Stock (ATXI) Company Profile

Avenue Therapeutics Inc

Healthcare (1112)

Biotechnology (621)

Nächster Verdiensttermin

Neueste SEC-Einreichungen

ATXI's Discussions on Twitter

Compare ATXI vs VRTX, REGN, ARGX, ALNY, ONC

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
ATXI Avenue Therapeutics Inc	0.18	0	0	-10.38M	-12.45M	-3.81
VRTX Vertex Pharmaceuticals Inc	486.50	121.97B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	782.00	81.49B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	769.04	47.74B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	331.45	43.93B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	318.33	35.67B	4.98B	69.60M	525.67M	0.5198

Avenue Therapeutics Inc Aktie (ATXI) Neueste Nachrichten

Finanzdaten der Avenue Therapeutics Inc-Aktie (ATXI)

Avenue Therapeutics Inc (ATXI)

Avenue Therapeutics Inc Stock (ATXI) Company Profile

Compare ATXI vs VRTX, REGN, ARGX, ALNY, ONC

Avenue Therapeutics Inc Aktie (ATXI) Neueste Nachrichten

Avenue Therapeutics licenses ATX-04 for Pompe disease treatment By Investing.com - Investing.com Australia

Avenue Therapeutics Licenses ATX-04 for Pompe Disease - TipRanks

Avenue Therapeutics licenses ATX-04 for Pompe disease treatment - Investing.com

After Menkes drug approval, Fortress moves to cash in $205M voucher - Stock Titan

Avenue Therapeutics Enters into Exclusive Worldwide License - GlobeNewswire

Lion Street Advisors LLC Buys 5,619 Shares of Axsome Therapeutics, Inc. $AXSM - MarketBeat

Candel Therapeutics Announces Pricing of Public Offering - The Manila Times

Context Therapeutics (NASDAQ:CNTX) Upgraded to Hold at Wall Street Zen - MarketBeat

Contineum Therapeutics (NASDAQ:CTNM) Rating Increased to Hold at Wall Street Zen - MarketBeat

Wall Street Zen Downgrades Kyverna Therapeutics (NASDAQ:KYTX) to Sell - MarketBeat

Warrant approval could dilute Dogwood Therapeutics (NASDAQ: DWTX) holders - Stock Titan

Cullinan Therapeutics (NASDAQ:CGEM) Rating Lowered to Sell at Wall Street Zen - MarketBeat

Edgewise Therapeutics (NASDAQ:EWTX) Downgraded by Wall Street Zen to Sell - MarketBeat

Maze Therapeutics (NASDAQ:MAZE) Lowered to "Sell" Rating by Wall Street Zen - MarketBeat

VIVOS Therapeutics, Inc. ($VVOS) Signs 12-Part Media Series with New to The Street - The Joplin Globe

Axsome Therapeutics says AXS-12 NDA submission on track for January - MSN

Century Therapeutics (NASDAQ:IPSC) Lowered to "Sell" Rating by Wall Street Zen - MarketBeat

Cullinan Therapeutics (NASDAQ:CGEM) Upgraded by Wall Street Zen to Hold Rating - MarketBeat

Esperion Therapeutics (NASDAQ:ESPR) Raised to "Buy" at Wall Street Zen - MarketBeat

TMC the metals (NASDAQ:TMC) vs. Canadian Zeolite (OTCMKTS:IZCFF) Critical Review - Defense World

Analyzing Turn Therapeutics (TTRX) & The Competition - Defense World

HCA Healthcare (NYSE:HCA) Shares Gap Up After Earnings Beat - Defense World

Boku (LON:BOKU) Insider Jonathan Peter Prideaux Sells 325,000 Shares of Stock - Defense World

Huge Waltham lab lease fuels work on potential Dravet syndrome drug - Stock Titan

Century Therapeutics (NASDAQ:IPSC) Stock Rating Upgraded by Wall Street Zen - MarketBeat

Wall Street Zen Upgrades Edgewise Therapeutics (NASDAQ:EWTX) to "Hold" - MarketBeat

Pacific Heights Asset Management LLC Raises Stake in Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat

TG Therapeutics, Inc. (NASDAQ:TGTX) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat

Fate Therapeutics (NASDAQ:FATE) Stock Price Crosses Above 50-Day Moving AverageHere's What Happened - MarketBeat

Maze Therapeutics (NASDAQ:MAZE) Cut to "Sell" at Wall Street Zen - MarketBeat

More cash flows into biotechs during conference week: Finance Report - biocentury.com

Aptevo Therapeutics (NASDAQ: APVO) seeks OK for $60M SEPA share sales - Stock Titan

Market Recap: Can Ernexa Therapeutics Inc continue delivering strong returnsJuly 2025 PostEarnings & Low Risk High Reward Ideas - baoquankhu1.vn

Avenue Therapeutics shareholders elect directors, ratify KPMG auditor - MSN

Early ZYCUBO treatment cut death risk nearly 80% in children with Menkes - Stock Titan

Capricor Therapeutics (NASDAQ:CAPR) Cut to Sell at Wall Street Zen - MarketBeat

Kyverna Therapeutics (NASDAQ:KYTX) Upgraded to "Hold" at Wall Street Zen - MarketBeat

Mersana Therapeutics (NASDAQ:MRSN) Upgraded at Wall Street Zen - MarketBeat

Karyopharm (NASDAQ: KPTI) plans big share authorization increase to fund 2026 trials - stocktitan.net

Is PTC Therapeutics Inc. stock a defensive play in 20252025 Price Targets & Smart Investment Allocation Tips - Улправда

Capricor Therapeutics (NASDAQ:CAPR) Upgraded at Wall Street Zen - MarketBeat

PTC Therapeutics (NASDAQ:PTCT) Upgraded to Buy at Wall Street Zen - MarketBeat

Avenue Therapeutics Provides Regulatory Update on IV Tramadol and Other Corporate Updates - ADVFN

Fortress Biotech, Cyprium Therapeutics and Sentynl Therapeutics Announce CUTX-101, Copper Histidinate, Data to be Presented at 2022 American College of Medical Genetics Annual Clinical Genetics Meeting - ADVFN

Avenue Therapeutics (ATXI) investors reelect six directors and ratify KPMG for 2025 - Stock Titan

Axsome Therapeutics shares gain 1.4% premarket after FDA grants priority review for co's Alzheimer's agitation drug - marketscreener.com

FDA supports Axsome’s NDA submission for narcolepsy drug AXS-12 By Investing.com - Investing.com Australia

CRX is an intrinsic suppressor of epithelial‒mesenchymal transition in retinal pigment epithelial cells: a promising therapeutic avenue for subretinal fibrosis | Cell Death & Disease - Nature

ATXI: All directors were elected and KPMG LLP was ratified as auditor for 2025 - TradingView — Track All Markets

ATXI: All director nominees were elected and KPMG LLP was ratified as auditor for 2025 - TradingView — Track All Markets

Finanzdaten der Avenue Therapeutics Inc-Aktie (ATXI)

Umsatz

Nettogewinn

Free Cashflow

ENV

Ähnlich wie ATXI